By Kellie Rademacher – Director, Strategy at Inizio Evoke
Market access is no longer about just getting a product covered, it’s also about ensuring the system can consistently deliver its value in the real world.
Across AMCP 2026, one message was clear: the rules of access are changing. Payers, providers, and policymakers are demanding more–more evidence, more coordination, and more accountability for outcomes. For manufacturers, this requires a shift from traditional access strategies to a broader, system-oriented approach.
Here are the five takeaways shaping that shift:
1. Coverage Is Table Stakes, Execution Is the Differentiator
Securing formulary access is no longer enough. Real-world gaps in testing, diagnosis, and treatment pathways continue to prevent patients from receiving appropriate therapy, even when it’s covered.
What it means:
The competitive battleground has moved to the “last mile” of access—how effectively therapies are activated and delivered in practice.
2. Evidence Must Be Real-World, Comparative, and Credible
Payers are increasingly relying on real-world evidence to inform decisions but they are also scrutinizing it more closely. Comparative data, transparent methodologies, and decision-relevant endpoints are now expected.
What it means:
Evidence is shifting from a supporting role to a core commercial asset, but only if it is credible and actionable.
3. Value Is Being Redefined Around Total Impact
Clinical efficacy alone no longer defines value. Payers are expanding their lens to include:
Total cost of care
Adherence and persistence
Quality of life and patient burden
However, patient-centered data must be quantified to influence decisions.
What it means:
Winning brands will be those that demonstrate holistic value across clinical, economic, and human outcomes.
4. Affordability Is Emerging as the New Access Barrier
Rising patient out-of-pocket costs are limiting uptake and adherence, even for covered therapies. This is particularly acute for high-need and lower-income populations.
What it means:
Access strategies must now address financial toxicity, not just reimbursement.
5. The Future of Access Is Integrated and Predictive
Healthcare is moving toward:
Integrated medical and pharmacy models
Data-driven decision-making
Predictive identification of high-risk patients
This enables earlier intervention and better management of outcomes and costs.
What it means:
Market access is evolving from reactive management to proactive value delivery.
The implication for manufacturers is clear:
Success in market access will depend not only on proving value, but on enabling the healthcare system to realize it.
This requires a new playbook, one that integrates evidence, affordability, patient experience, and system execution into a cohesive strategy.
Interested in hearing more? Connect with us here.